Search company, investor...
Recursion company logo

Recursion

recursion.com

Founded Year

2013

Stage

Corporate Minority - P2P | IPO

Total Raised

$509.79M

Market Cap

1.59B

Stock Price

8.38

Revenue

$0000 

About Recursion

Recursion (NASDAQ: RXRX) is a clinical-stage biotechnology company combining experimental biology and automation with artificial intelligence in a parallel system to efficiently discover potential drugs for diverse indications, including genetic disease, inflammation, immunology, and infectious disease. The company was founded in 2013 and is based in Salt Lake City, Utah.

Headquarters Location

41 S Rio Grande St

Salt Lake City, Utah, 84101,

United States

385-269-0203

Missing: Recursion's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Recursion's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Recursion

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Recursion is included in 8 Expert Collections, including Digital Health.

D

Digital Health

21,956 items

Startups recreating how healthcare is delivered

A

AI 100

299 items

C

Conference Exhibitors

5,501 items

HLTH is a healthcare event bringing together startups and large companies from pharma, health insurance, business intelligence, and more to discuss the shifting landscape of healthcare

A

Artificial Intelligence

9,442 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

D

Digital Health 150

300 items

2019's cohort of the most promising digital health startups transforming the healthcare industry

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Recursion Patents

Recursion has filed 1 patent.

The 3 most popular patent topics include:

  • Biotechnology
  • Genetics
  • Molecular biology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/20/2020

11/15/2022

Drug discovery, Fault tolerance, Medicinal chemistry, Parallel computing, Cheminformatics

Grant

Application Date

7/20/2020

Grant Date

11/15/2022

Title

Related Topics

Drug discovery, Fault tolerance, Medicinal chemistry, Parallel computing, Cheminformatics

Status

Grant

Latest Recursion News

Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Tops Revenue Estimates

Nov 9, 2022

Nasdaq By Zacks Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.28 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 2.78%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.35 per share when it actually produced a loss of $0.38, delivering a surprise of -8.57%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. AD AD Recursion Pharmaceuticals, which belongs to the Zacks Medical - Drugs industry, posted revenues of $13.16 million for the quarter ended September 2022, surpassing the Zacks Consensus Estimate by 104.57%. This compares to year-ago revenues of $2.53 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Recursion Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Recursion Rank

Recursion Frequently Asked Questions (FAQ)

  • When was Recursion founded?

    Recursion was founded in 2013.

  • Where is Recursion's headquarters?

    Recursion's headquarters is located at 41 S Rio Grande St, Salt Lake City.

  • What is Recursion's latest funding round?

    Recursion's latest funding round is Corporate Minority - P2P.

  • How much did Recursion raise?

    Recursion raised a total of $509.79M.

  • Who are the investors of Recursion?

    Investors of Recursion include Baillie Gifford & Co., Mubadala Investment Company, Laurion Capital Management, Platinum Investment Management, Kinnevik and 29 more.

  • Who are Recursion's competitors?

    Competitors of Recursion include Insilico Medicine, Cyclica, nference, METiS Therapeutics, BenevolentAI, Terray Therapeutics, Exscientia, XtalPi, BioSymetrics, BioMap and 17 more.

Compare Recursion to Competitors

insitro Logo
insitro

insitro is a data-driven drug discovery and development company that leverages machine learning and high-throughput biology to transform the way medicines are created to help patients.

Atomwise Logo
Atomwise

Atomwise uses deep learning neural networks to help discover new medicines. Atomwise achieves results for new drug hit discovery, binding affinity prediction, and toxicity detection. Atomwise predicts drug candidates for pharmaceutical companies, start-ups, and research institutions. It is currently using computational drug design to design drugs against COVID.

Insilico Medicine Logo
Insilico Medicine

Insilico Medicine develops a range of Generative Adversarial Networks (GANs) and reinforcement learning approaches to identify protein targets, generate molecular structures with specified properties, and generate synthetic data. The company provides pharmaceutical and biotechnology companies with artificial intelligence solutions for research and development. It was founded in 2014 and is based in Hong Kong.

Cyclica Logo
Cyclica

Cyclica offers artificial intelligence (AI) and computational biophysics based drug discovery process. Its structure-based and artificial intelligence (AI) augmented drug discovery platform includes Ligand Design for multi-targeted and multi-objective drug design, and Ligand Express for off-target profiling, systems biology linkages, and structural pharmacogenomic insights. The company was founded in 2013 and is based in Toronto, Canada.

Healx Logo
Healx

Healx is an AI-powered and patient-inspired technology company, accelerating the discovery and development of rare disease treatments. Its AI drug discovery platform leverages public and proprietary biomedical data and features a knowledge graph for rare diseases.

Aria Pharmaceuticals Logo
Aria Pharmaceuticals

Aria Pharmaceuticals is a preclinical-stage pharmaceutical company that discovers and develops novel small molecule therapies for complex and hard-to-treat diseases

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.